Merck’s Animal Health business generated $1.775 billion in second-quarter 2026 sales, driven by growth across both livestock and companion animal portfolios, while the company also completed its acquisition of poultry technology company TARGAN.
Merck Animal Health has received FDA approval for NUMELVI™ (atinvicitinib tablets), the first and only second-generation JAK inhibitor indicated for control of pruritus associated with allergic dermatitis in dogs six months of age and older.
Merck reported full-year 2025 worldwide sales of $65.0 billion, supported by strong performance in oncology and animal health and growing contributions from newer product launches.
Mexico’s SADER approved Merck Animal Health’s EXZOLT® 5% Pour-On (fluralaner 50 mg/mL) for the prevention and treatment of New World Screwworm larvae, strengthening cattle protection and supporting Mexico’s beef industry.
Merck’s Animal Health segment grew 9% to $1.6B in the third quarter of 2025, driven by strong livestock demand; companion animal dipped 2% amid parasiticide competition and fewer vet visits.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.